News Releases

December 12, 2019
*** This is a test sample for GLOBE NEWSWIRE quarterly results release style. It will need to be removed before the site is set to live. *** Second quarter revenue increased to $11.6 million compared to $4.6 million in the same period last year. Received a strategic investment of $100 million from
December 3, 2019
*** This is a test sample for PRNewswire quarterly results release style. It will need to be removed before the site is set to live. *** DIVISIONR (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx DIVISION? (elagolix), the First FDA-Approved Oral
October 10, 2019
DURHAM, NC – October 10, 2019 – In support of World Arthritis Day, which is celebrated every October 12 to raise awareness of arthritis, Bioventus , a global leader in orthobiologics, has launched a disease and product information website called OAKneePainRelief.com which combines information on
March 27, 2019
DURHAM, NC – March 27, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEO AMP SELECT Fibers , an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.
January 29, 2019
HOOFDDORP, THE NETHERLANDS – January 29, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market.
January 15, 2019
DURHAM, NC – January 15, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of
Displaying 21 - 30 of 38